Bristol-Myers Squibb (BMS) has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed bag of new hires, sideways moves, and departures.
The contingent value right (CVR) offered by BMS as a sweetener for the $74 billion takeover of Celgene in 2019 is defunct, as one of the three drugs – CAR-T therapy liso-cel for lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback